4.5 Article

Identification of Clinical and Genetic Parameters Associated with Hidradenitis Suppurativa in Inflammatory Bowel Disease

Journal

INFLAMMATORY BOWEL DISEASES
Volume 22, Issue 1, Pages 106-113

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MIB.0000000000000579

Keywords

Crohn's disease; hidradenitis suppurativa; inflammatory bowel disease; ulcerative colitis; risk factors

Funding

  1. VIDI grant from the Netherlands Organization for Scientific Research (NWO) [016.136.308]

Ask authors/readers for more resources

Background: Hidradenitis suppurativa (HS) has recently been associated with inflammatory bowel disease (IBD). The objective of this study is to investigate the prevalence of HS in IBD and to identify clinical and genetic parameters associated with HS in IBD. Methods: A questionnaire, validated for HS, was sent to 1969 patients suffering from IBD. Results: The prevalence of HS in our IBD cohort (1260 participating patients) was significantly higher than in the general population (6.8%-10.6% versus 1%-2%). IBD patients with HS were affected by IBD significantly earlier and more often treated with anti-TNF-alpha therapy and surgical resection compared to IBD without HS. Female gender, smoking, a higher body mass index, and younger age were independent associated parameters for HS. Within cases allelic association analysis was performed for 59 cases (IBD with HS) and 293 controls (IBD without HS). We observed 2 promising new associations in genomic regions harboring ELOVL7 (rsnumber 10057395 P = 7.15 x 10(-5), odds ratio = 0.4), and in the intergenic region between SULT1B1 and SULT1E1 (rsnumber 2014777 P = 7.48 x 10(-5), odds ratio = 2.3). Conclusions: HS is present in 6.8% to 10.6% of IBD patients. Co-morbid HS is associated with an early onset of IBD in which anti-tumor necrosis factor-a therapy and surgical resections are often needed. We identified a suggestive protective association with ELOVL7 and suggestive risk association with the genes SULT1B1 and SULT1E1 for HS, in the context of IBD. These genetic associations need further exploration and replication in additional independent cohorts.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Dermatology

Paraneoplastic pemphigus: A detailed case series from the Netherlands revealing atypical cases

Farhat Zaheri, Hendri H. Pas, Jeroen Bremer, Joost M. Meijer, Marieke C. Bolling, Barbara Horvath, Gilles F. H. Diercks

Summary: This study aimed to analyze a cohort of Dutch patients with paraneoplastic pemphigus (PNP) and identify atypical cases that did not meet the diagnostic criteria. The results showed several patients who did not completely meet the set criteria.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

Chronic Use of Hydrochlorothiazide and Risk of Skin Cancer in Caucasian Adults: A PharmLines Initiative Inception Cohort Study

Marjolijn S. Haisma, Mathanhy Logendran, Jens Bos, Bert V.d. Vegt, Barbara Horvath, Stijn DE Vos, Geertruida H. D. E. Bock, Eelko Hak, Emoke Racz

Summary: This study investigated the association between hydrochlorothiazide use and skin cancer incidence. It found a clear association between high cumulative hydrochlorothiazide use and the risk of different types of skin cancer.

ACTA DERMATO-VENEREOLOGICA (2023)

Article Urology & Nephrology

Proton Pump Inhibitor Use, Fatigue, and Health-Related Quality of Life in Kidney Transplant Recipients: Results From the Transplant Lines Biobank and Cohort Study

Tim J. Knobbe, Daan Kremer, Rianne M. Douwes, Michele F. Eisenga, Antonio W. Gomes-Neto, Coby Annema, J. Casper Swarte, Frank Klont, Gerjan Navis, Stefan P. Berger, Stephan J. L. Bakker

Summary: Prior studies have shown that the use of proton pump inhibitors (PPIs) can negatively impact gut microbiota and the absorption of micronutrients, such as iron and magnesium. This study aims to investigate the association between PPI use and fatigue and health-related quality of life (HRQoL) in kidney transplant recipients.

AMERICAN JOURNAL OF KIDNEY DISEASES (2023)

Article Infectious Diseases

Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

Koos P. J. G. van Dam, Adriaan Volkers, Luuk W. Wieske, Eileen Stalman, Laura Y. L. Kummer, Zoe L. E. van Kempen, Joep W. Killestein, Sander Tas, Laura J. Boekel, Gerrit J. Wolbink, Anneke van der Kooi, Joost Raaphorst, R. Bart Takkenberg, Geert R. A. M. I. D'Haens, Phyllis W. Spuls, Marcel H. Bekkenk, Annelie F. Musters, Nicoline L. Post, Angela L. Bosma, Marc Hilhorst, Yosta J. Vegting, Frederike E. Bemelman, Alexandre Voskuyl, Bo Broens, Agner Parra Sanchez, Cecile A. C. M. van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horvath, Jan J. G. M. M. Verschuuren, Annabel Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Renee C. F. Allaart, Y. K. Onno Teng, Pieter H. van Paassen, Matthias Busch, Papay B. P. Jallah, Esther A. Brusse, Pieter van Doorn, Adaja E. Baars, Dirk Jan Hijnen, Corine R. G. Schreurs, W. Ludo van der Pol, H. Stephan Goedee, Maurice Steenhuis, Sofie Keijzer, Jim B. D. Keijser, Olvi Cristianawati, Anja ten Brinke, Niels J. M. Verstegen, S. Marieke van Ham, Theo W. Rispens, Taco Kuijpers, Mark Lowenberg, Filip Eftimov

Summary: This study investigated the long-term humoral immune responses to SARS-CoV-2 and increased disease activity after a primary infection in unvaccinated patients with immune-mediated inflammatory diseases (IMIDs) using immunosuppressants (ISPs). The results showed that IMID patients using ISPs had reduced long-term humoral immune responses after SARS-CoV-2 infection, especially those using anti-CD20 and anti-tumor necrosis factor (TNF) agents. Increased disease activity after infection was commonly reported, but mostly mild.

BMC INFECTIOUS DISEASES (2023)

Article Dermatology

Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study

Koen Dudink, Klasiena Bouwman, Yanqing Chen, Samuel E. DePrimo, Ernesto J. Munoz-Elias, Pim Aarts, Renske Schappin, Edwin F. Florencia, Bennie van Heeswijk, Lisette M. Prens, Hessel H. van der Zee, Errol P. Prens, Kelsey R. van Straalen, Barbara Horvath

Summary: 65% of patients with moderate-to-severe hidradenitis suppurativa achieved a clinical response after 16 weeks of guselkumab treatment, which was well tolerated. Transcriptomic data supported the rationale for IL-23 inhibition with guselkumab, but did not consistently correlate with protein expression and clinical responses. Guselkumab seems to be beneficial only in a subgroup of HS patients, suggesting that the IL-23/T helper 17 axis is not central to the pathophysiology of HS.

BRITISH JOURNAL OF DERMATOLOGY (2023)

Review Dermatology

Heterogeneity of reported outcomes in epidermolysis bullosa clinical research: a scoping review as a first step towards outcome harmonization

Eva W. H. Korte, Tobias Welponer, Jan Kottner, Sjoukje van der Werf, Peter C. van den Akker, Barbara Horvath, Dimitra Kiritsi, Martin Laimer, Anna M. G. Pasmooij, Verena Wally, Maria C. Bolling

Summary: This study summarizes the different outcomes and outcome measurement instruments reported in clinical research on epidermolysis bullosa (EB) over the past 30 years and identifies a significant heterogeneity. Adequate evaluation and comparison of EB clinical studies require well-defined and consensus-endorsed outcomes and measurement instruments. This scoping review is the first step towards harmonization of EB outcomes, which is crucial for the clinical translation of novel treatments.

BRITISH JOURNAL OF DERMATOLOGY (2023)

Article Gastroenterology & Hepatology

Temporary diverting stoma in therapy-refractory luminal colonic Crohn's disease: an alternative to immediate colorectal resection?

Adrianus. M. van Der Holst, Antonius T. Otten, Elise M. Meima-van Praag, Alexander R. P. K. M. van Renterghem, Arno R. Bourgonje, Ellen S. van Loo, Gerard Dijkstra, Christianne J. Buskens, Laurents P. S. Stassen

Summary: Creation of a diverting stoma in patients with Crohn's disease may counteract luminal inflammation. This study aimed to evaluate the long-term effects of a diverting stoma on the disease course. Findings suggest that a diverting stoma could be an alternative in specific populations of patients with luminal colonic CD, especially in the absence of proctitis.

COLORECTAL DISEASE (2023)

Article Gastroenterology & Hepatology

Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab

Roberta Loveikyte, Arno R. Bourgonje, Johannes J. van der Reijden, Marian L. C. Bulthuis, Lukas J. A. C. Hawinkels, Marijn C. Visschedijk, Eleonora A. M. Festen, Hendrik M. van Dullemen, Rinse K. Weersma, Harry van Goor, Andrea E. van der Meulen-de Jong, Gerard Dijkstra

Summary: Absolute iron deficiency is the main factor determining hepcidin levels, even in an inflammatory state. Induction therapy can decrease hepcidin levels, which may improve the availability of iron. Therefore, hepcidin is a potential diagnostic biomarker for iron deficiency and can assist in therapeutic decision making.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease

Antonius T. Otten, Hedwig H. van der Meulen, Maurice Steenhuis, Floris C. Loeff, Daan J. Touw, Jos G. W. Kosterink, Henderik W. Frijlink, Theo Rispens, Gerard Dijkstra, Marijn C. Visschedijk, Arno R. Bourgonje

Summary: A finger prick-based capillary blood self-sampling technique was validated for monitoring infliximab, vedolizumab, and C-reactive protein concentrations in patients with inflammatory bowel disease. The technique received substantial support from patients and demonstrated good tolerability and practicality.

INFLAMMATORY BOWEL DISEASES (2023)

Article Medicine, General & Internal

Effects of ileocolonic delivered vitamin B2, B3 and C (ColoVit) or the Groningen anti-inflammatory diet on disease course and microbiome of patients with Crohn's disease (VITA-GrAID study): a protocol for a randomised and partially blinded trial

Antonius Timotheus Otten, V Peters, I Barth, C. L. Stevens, A. R. Bourgonje, H. W. Frijlink, H. J. M. Harmsen, A. Rehman, M. J. E. Campmans-Kuijpers, G. Dijkstra

Summary: This article describes a nutritional intervention trial on patients with Crohn's disease (CD) and their healthy household members, investigating the effects of an evidence-based anti-inflammatory diet and an ileocolonic-targeted capsule containing vitamin B2, B3, and C. The results of the study will provide valuable evidence for dietary recommendations for CD patients and physicians.

BMJ OPEN (2023)

Article Pharmacology & Pharmacy

Hospital Admission Profile Related to Inner Ear Diseases in England and Wales

Aisha A. Ahmed, Antonius T. Otten, Bahez Gareb, Judith E. Huijmans, Anko C. Eissens, Ateequr Rehman, Gerard Dijkstra, Jos G. W. Kosterink, Henderik W. Frijlink, Reinout C. A. Schellekens

Summary: The development of capsules containing riboflavin, nicotinic acid, and ascorbic acid covered with a pH-sensitive coating (ColoVit) was described to achieve site-specific release in the ileocolon. The capsules met the required specifications and had a lag-time in drug release of 277-283 min, which meets the requirements for ileocolonic release. The production process of the ColoVit formulation was validated and reproducible, and the vitamin blend was stable during the production process and in the finished coated product. ColoVit is intended as an innovative treatment approach for beneficial microbiome modulation and optimization of gut health.

PHARMACEUTICS (2023)

Letter Gastroenterology & Hepatology

The Future of Therapeutic Drug Monitoring in Inflammatory Bowel Disease: An Emphasis on the Essential Ingredients

Antonius T. Otten, Gerard Dijkstra, Marijn C. Visschedijk, Arno R. Bourgonje

INFLAMMATORY BOWEL DISEASES (2023)

Review Biochemistry & Molecular Biology

The NRF2/Keap1 pathway as a therapeutic target in inflammatory bowel disease

Sem Geertsema, Arno R. Bourgonje, Raphael R. Fagundes, Ranko Gacesa, Rinse K. Weersma, Harry van Goor, Giovanni E. Mann, Gerard Dijkstra, Klaas N. Faber

Summary: Oxidative stress is an important mechanism in inflammatory bowel disease. The NRF2/Keap1 pathway regulates cellular responses to oxidative stress and has been implicated in the development of inflammatory bowel disease. Activation of the NRF2/Keap1 pathway enhances antioxidant responses and may potentially improve clinical outcomes for inflammatory bowel disease.

TRENDS IN MOLECULAR MEDICINE (2023)

Review Immunology

cGAS-STING signaling pathway in intestinal homeostasis and diseases

Yuchen Yang, Li Wang, Ivonne Peugnet-Gonzalez, Daniela Parada-Venegas, Gerard Dijkstra, Klaas Nico Faber

Summary: The intestinal mucosa serves as a barrier and is involved in nutrient absorption. Genetic susceptibility and environmental factors play a critical role in the development of intestinal diseases. The innate immune system recognizes potential threats through pattern recognition receptors (PRRs), including the cGAS-STING pathway. However, the role of the cGAS-STING pathway in intestinal diseases is still debated.

FRONTIERS IN IMMUNOLOGY (2023)

Article Rheumatology

Psoriasis seems often underdiagnosed in patient with axial spondyloarthritis

Angelique Rondags, Laura van Marle, Barbara Horvath, Freke R. Wink, Suzanne Arends, Anneke Spoorenberg

Summary: This study found that psoriasis is often underdiagnosed in patients with axial spondyloarthritis (axSpA), and a patient self-reported questionnaire with prototypical pictures to recognize psoriasis symptoms could be beneficial in tracing undiagnosed psoriasis.

ARTHRITIS RESEARCH & THERAPY (2023)

No Data Available